Where Will Iovance Biotherapeutics Be in 5 Years?

Iovance Biotherapeutics (NASDAQ: IOVA), a small-cap biotech company, has an innovative approach to treating cancer that relies on harnessing patients' cancer-fighting capabilities. Though the company has encountered some success, including a crucial regulatory approval coming down last year, that hasn't been enough to seduce investors. Iovance's shares are down by 71% in the past five years.Can the company turn things around and perform much better through the end of the decade? Let's find out.First, a little more detail on Iovance's approach. The company seeks to develop therapies that enhance patients' cancer-fighting cells, specifically tumor-infiltrating lymphocytes (TILs). Iovance collects these cells from a patient and uses them to manufacture treatments before reinserting them back into the patient. That's the procedure behind the company's Amtagvi, a medicine for advanced melanoma that was approved in February 2024.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool